Creative Medical Technology vs Alaunos Therapeutics
CELZ and TCRT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELZ and TCRT compare
Creative Medical Technology and Alaunos Therapeutics are about the same size, with market caps of $4.1M and $4.1M.
Creative Medical Technology grew revenue faster over the last twelve months (−50.0% versus −50.0% for Alaunos Therapeutics).
Alaunos Therapeutics keeps more of each dollar of sales as profit, with a net margin of −133667% compared with −249160% at Creative Medical Technology.
Creative Medical Technology scores higher on the StockData Score (7 against 4 for Alaunos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELZ | TCRT |
|---|---|---|
| Size and price | ||
| Market cap | $4.1M | $4.1M |
| Share price | $0.617 | $1.62 |
| Change, 1 year | −80.7% | −42.8% |
| Change, 5 years | −98.2% | −99.2% |
| Beta (5Y) | 1.55 | −0.43 |
| Employees | – | 1 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1355× (better) | 1372× |
| P/B | 0.6× (better) | 6.3× |
| Growth | ||
| Revenue growth (TTM) | −50.0% | −50.0% |
| Revenue growth, 5Y average | −48.4% | – |
| Profitability | ||
| Gross margin | 66.9% | – |
| Operating margin | −256435% | −135267% (better) |
| Net margin | −249160% | −133667% (better) |
| Return on equity | −119% (better) | −186% |
| Return on invested capital | −3737% | −489% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 23.66 (better) | 0.77 |
| Altman Z-score | −8.73 (better) | −861.81 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −194% | – |
| Shareholder yield | −194% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 5.7% | 3.6% |
| Held by insiders | 15.9% | 69.8% |
| Short interest, % of float | 1.2% | 24.0% |
Go deeper
- CELZ stock overview
- CELZ income statement
- CELZ valuation and score
- TCRT stock overview
- TCRT income statement
- TCRT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.